Today: 21 May 2026
Ethereum Price Today (Nov 12, 2025): ETH Steadies Near $3,545 as ETF Outflows and Macro Uncertainty Weigh
12 November 2025
2 mins read

Ethereum Price Today (Nov 12, 2025): ETH Steadies Near $3,545 as ETF Outflows and Macro Uncertainty Weigh

Ethereum (ETH) is trading around $3,544–$3,548 today (Nov 12, 2025), slipping by roughly 1% over the past 24 hours. Intraday, ETH has ranged between $3,405 and $3,591 while broader crypto markets consolidate. Bitcoin is hovering near $104,900, also fractionally lower on the day.


ETH price at a glance

  • Spot price: ~$3,545
  • 24h range: $3,405 – $3,591
  • 24h momentum: Mildly negative; majors broadly flat to slightly down
  • Context: Market tone cautious after several days of choppy trade; privacy tokens led gains while large caps stalled.

What moved Ethereum today

ETF flows turned net negative for Ether yesterday (Nov 11, ET), with U.S. spot ETH ETFs recording about $107 million in net outflows across the complex. That steady drip of redemptions has pressured sentiment around ETH even as Bitcoin ETFs saw renewed inflows.

Macro clouds linger. A prolonged U.S. government shutdown has delayed key economic releases, keeping traders on edge. As Washington moves to reopen, markets are bracing for the data deluge to resume, which could reset risk appetite across crypto.

Rotation and the ETF race matter. Analysts are watching capital flows across the newest altcoin ETFs after Bitwise’s Solana ETF drew rapid attention—an example of how fresh, regulated vehicles can tug at investor attention and liquidity across the non‑Bitcoin complex.

Institutional narrative remains constructive for Ethereum. A former BlackRock executive this week called Ethereum “the infrastructure” for Wall Street tokenization—supportive long‑term framing even as near‑term flows wobble. CoinDesk


On‑chain and activity snapshot

Usage is subdued but stable. Ethereum’s on‑chain and DeFi activity show a cooling from recent peaks, consistent with today’s rangebound price action:

  • Ethereum DEX volume (24h): roughly $2.37B
  • Active addresses (24h): ~464k

Lower fee and volume regimes have persisted since 2024’s scalability upgrades, which pushed more activity to Layer‑2s and made base‑layer usage cheaper—supportive for end‑users, if occasionally a headwind for fee‑driven narratives.


Technical picture (intraday)

  • Immediate support: $3,405–$3,430 (today’s low / prior demand zone)
  • Near‑term resistance: $3,585–$3,600 (today’s high / round‑number supply)
  • Bias: Sideways to slightly heavy while ETF flow and macro catalysts dominate tape reading.

Numbers above reflect today’s real‑time high/low band; momentum could shift quickly around upcoming data releases.


Key storylines to watch next

  1. U.S. CPI (October) – scheduled for Thursday, Nov 13. A hot or cool read can ripple through rates, the dollar, and crypto risk appetite.
  2. Daily ETH ETF flow prints. Persistent outflows tend to cap rallies; a flip back to inflows could provide fuel.
  3. ETF competition across chains. The expanding menu of altcoin ETFs (and their fee structures) may keep reshuffling capital within the large‑cap set.
  4. Institutional tokenization headlines. Continued moves by TradFi players to build on or around Ethereum sustain the “infrastructure” thesis even when price chops. CoinDesk

Bottom line

Ethereum is marking time near $3.55k after a soft 24 hours, with ETF outflows and data‑dependent macro caution setting the tone. The intraday band ($3.41k–$3.59k) defines today’s battle line; the next decisive push likely comes from Thursday’s CPI and the next round of ETF flow disclosures. Until then, expect chop with a macro leash.


Methodology & sources

Live price and range are pulled from real‑time market feeds; market color reflects cross‑checks with reputable financial and crypto publications and data dashboards including CoinDesk (markets wrap), Farside/SoSoValue (ETF flow trackers), Reuters (macro/market context), and DeFiLlama (on‑chain activity metrics).

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Stock Market on Edge: U.S. Futures Slide as US-China Trade War Heats Up
Previous Story

5 Stocks to Buy Today (12.11.2025): AMD, On Holding, Cisco, Chevron, BILL

Anthropic’s Private Shares Soar to $185 Amid AI Frenzy – $183B Valuation, Major Deals & $1.5B Lawsuit
Next Story

Anthropic Poised to Beat OpenAI to Profitability as It Diversifies Beyond Nvidia — What’s New Today (Nov. 12, 2025)

Go toTop